Vladimir Vexler - Coherus BioSciences Chief Scientific Officer
| CHRS Stock | USD 1.26 0.02 1.56% |
Executive
Dr. Vladimir Vexler Ph.D is Chief Scientific Officer of the company. Dr. Vexler served as our Senior Vice President of Translational Development Sciences since June 2016, and our Vice President, Preclinical Development since January 2013. Prior to that, Dr. Vexler was a Senior Research Leader, Biotherapeutics at HoffmanLa Roche, where he acted as Global scientific leader for nonclinical safety of biotherapeutics and chaired Roche pRED Global Biotherapeutics Safety Team since December 2009. Dr. Vexler began his career as a postdoctoral fellow at the Department of Radiology at UCSF since 2018.
| Age | 66 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 |
| Phone | 650 649 3530 |
| Web | https://www.coherus.com |
Coherus BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.1403) % which means that it has lost $0.1403 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.97 in 2024, whereas Return On Tangible Assets are likely to drop (0.45) in 2024. At this time, Coherus BioSciences' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 74.8 M in 2024, whereas Total Current Assets are likely to drop slightly above 311.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nathan Ihle | Bolt Biotherapeutics | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| PharmD BCOP | Bolt Biotherapeutics | N/A | |
| Steven CPA | NextCure | 61 | |
| Sourav Kundu | NextCure | 63 | |
| Stacy Rollinger | NextCure | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Udayan MD | NextCure | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Kevin Shaw | NextCure | 49 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Amy CFA | Assembly Biosciences | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 |
Coherus BioSciences Leadership Team
Elected by the shareholders, the Coherus BioSciences' board of directors comprises two types of representatives: Coherus BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coherus. The board's role is to monitor Coherus BioSciences' management team and ensure that shareholders' interests are well served. Coherus BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coherus BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vladimir Vexler, Chief Scientific Officer | ||
| Bryan Mcmichael, Principal Accounting | ||
| Dennis Lanfear, Chairman, CEO and Pres | ||
| Michael Chen, Senior Trade | ||
| Theresa Lavallee, Chief Board | ||
| MRCP MD, Chief Officer | ||
| Rebecca Sunshine, Chief Officer | ||
| Scott Saywell, Executive Development | ||
| Jodi Sievers, Vice Communications | ||
| Karen Kotz, Ex Accounts | ||
| Jami Taylor, Vice Relations | ||
| Christopher Slavinsky, Chief Officer | ||
| Cheston Turbyfill, Vice Communications | ||
| Andy Rittenberg, Executive Counsel | ||
| McDavid Stilwell, Chief Officer | ||
| Paul Reider, Chief Officer | ||
| Richard Hameister, Chief Officer |
Coherus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coherus BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 317.35 M | ||||
| Shares Outstanding | 115.21 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 70.09 % | ||||
| Number Of Shares Shorted | 33.04 M | ||||
| Price To Earning | 4.22 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.